Acromegaly and its treatment in the McCune‐Albright syndrome
- 1 June 1992
- journal article
- case report
- Published by Wiley in Clinical Endocrinology
- Vol. 36 (6) , 605-608
Abstract
The McCune-Albright syndrome, comprising polyostotic fibrous dysplasia, cutaneous pigmentation and endocrine hyperfunction, is occasionally complicated by acromegaly due to a pituitary adenoma. We report a patient with the McCune-Albright syndrome and acromegaly, who developed secondary hypothyroidism and hypoadrenalism, in whom surgical removal of the pituitary tumour was technically difficult. A combination of a long-acting somatostatin analogue ('Sandostatin') and external irradiation were therefore used as treatment.Keywords
This publication has 7 references indexed in Scilit:
- CLINICAL REVIEW 22 Therapeutic Options in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 1991
- A CLOSE CORRELATION BETWEEN THE INHIBITORY EFFECTS OF INSULIN‐LIKE GROWTH FACTOR‐I AND SMS 201‐995 ON GROWTH HORMONE RELEASE BY ACROMEGALIC PITUITARY TUMOURS IN VITRO AND IN VIVOClinical Endocrinology, 1989
- Hypersecretion of Growth Hormone and Prolactin in McCune-Albright Syndrome*The Journal of Clinical Endocrinology & Metabolism, 1989
- The Growth Hormone Responses to Octreotide in Acromegaly Correlate with Adenoma Somatostatin Receptor StatusThe Journal of Clinical Endocrinology & Metabolism, 1989
- Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndromeThe Journal of Pediatrics, 1987
- Treatment of Resistant Acromegaly with a Long-Acting Somatostatin Analogue (SMS 201-995)Annals of Internal Medicine, 1986
- Syndrome Characterized by Osteitis Fibrosa Disseminata, Areas of Pigmentation and Endocrine Dysfunction, with Precocious Puberty in FemalesNew England Journal of Medicine, 1937